Holen Sie sich die Stockscreener-App
13.41
0.52%
0.07
Vorhandelsmarkt:
13.41
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
(KROS) Trading Report - news.stocktradersdaily.com
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat
Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener
BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com
KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize
Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa
ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com
Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan
Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus
Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks
Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com
Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times
Keros Therapeutics to return $375 million to shareholders - Investing.com
Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review - Nasdaq
Keros Concludes Strategic Review: Massive $375M Shareholder Return While Advancing DMD Drug Development - Stock Titan
Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Wellington Management Group LLP - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP - Defense World
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Two Sigma Advisers LP Has $328,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat
ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World
D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):